Study protocol: safety and efficacy of propranolol 0.2% eye drops in newborns with a precocious stage of retinopathy of prematurity (DROP-ROP-0.2%): a multicenter, open-label, single arm, phase II trial
Abstract Background Retinopathy of prematurity (ROP) still represents one of the leading causes of visual impairment in childhood. Systemic propranolol has proven to be effective in reducing ROP progression in preterm newborns, although safety was not sufficiently guaranteed. On the contrary, topica...
Saved in:
Similar Items
-
Propranolol 0.2% Eye Micro-Drops for Retinopathy of Prematurity: A Prospective Phase IIB Study
by: Luca Filippi, et al.
Published: (2019) -
Refractive Outcome in Preterm Newborns With ROP After Propranolol Treatment. A Retrospective Observational Cohort Study
by: Luca Filippi, et al.
Published: (2019) -
Comparative clinical and microbiological efficacy of mouthwashes containing 0.2% and 0.12% chlorhexidine
by: S K Rath, et al.
Published: (2013) -
Epidural labor analgesia: A comparison of ropivacaine 0.125% versus 0.2% with fentanyl
by: Yogesh Kumar Chhetty, et al.
Published: (2013) -
Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491
by: Isacchi Benedetta, et al.
Published: (2010)